Address correspondence to Dr Susanne Muehlschlegel, Departments of Neurology, Anesthesia/Critical Care & Surgery, University of Massachusetts Medical School, University Campus, S-5, 55 Lake Ave N, Worcester, MA 01655, email@example.com.
RELATIONSHIP DISCLOSURE: Dr Muehlschlegel has received research/grant support from the National Institutes of Health/National Institute of Child Health and Human Development and the Prize for Academic Collaboration and Excellence (PACE) from the University of Massachusetts Memorial Medical Group. Dr Muehlschlegel receives partial research salary support as the site principal investigator for the INTREPID (Impact of Fever Prevention Continued on page 1657in Brain Injured Patients) trial sponsored by C. R. Bard Inc. Dr Muehlschlegel has received compensation for serving as a course director for the American Academy of Neurology.
UNLABELED USE OF PRODUCTS/INVESTIGATIONAL USE DISCLOSURE: Dr Muehlschlegel discusses the unlabeled/investigational short-term use of antifibrinolytics (ε-aminocaproic acid and tranexamic acid) for the treatment of early aneurysm bleeding, the use of fludrocortisone for the treatment of cerebral salt wasting syndrome after subarachnoid hemorrhage, the use of levetiracetam for seizure prophylaxis, and the use of milrinone, nicardipine, and verapamil as endovascular therapy using intraarterial vasodilators for the treatment of subarachnoid hemorrhage.
CONTINUUM AUDIO INTERVIEW AVAILABLE ONLINE